An Bioequivalence Study Of Xanax Extended Release Tablets From Two Different Manufacturing Sites

An Open Label, Randomized, Single Dose, Crossover Pivotal Bioequivalence Study Of Xanax XR Tablet 3 mg (Sourced From Caguas) Versus Xanax XR Tablet 3 mg (Sourced From Barceloneta) In Healthy Subjects

Study to evaluate if Xanax sustained release tablets manufactured at two different sites provide similar drug levels in the blood.

Inclusion Criteria:

• Healthy male and/or female subjects between the ages of 20 and 55 years, inclusive.
• An informed consent document signed and dated by the subject.

Exclusion Criteria:

• Evidence or history of clinically significant abnormality.
• A positive urine drug screen.
• Subjects who are hypersensitive to alprazolam or related compounds.